Guillermo Paez , Clinical Response to Gefitinib Therapy Mutations in Lung Cancer : Correlation withEGFR
نویسنده
چکیده
http://www.sciencemag.org/cgi/content/full/304/5676/1497 version of this article at: including high-resolution figures, can be found in the online Updated information and services, http://www.sciencemag.org/cgi/content/full/1099314/DC1 can be found at: Supporting Online Material found at: can be related to this article A list of selected additional articles on the Science Web sites http://www.sciencemag.org/cgi/content/full/304/5676/1497#related-content http://www.sciencemag.org/cgi/content/full/304/5676/1497#otherarticles , 21 of which can be accessed for free: cites 26 articles This article 1442 article(s) on the ISI Web of Science. cited by This article has been http://www.sciencemag.org/cgi/content/full/304/5676/1497#otherarticles 93 articles hosted by HighWire Press; see: cited by This article has been http://www.sciencemag.org/cgi/collection/medicine Medicine, Diseases : subject collections This article appears in the following
منابع مشابه
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in...
متن کاملCombined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
PURPOSE Somatic mutations of the epidermal growth factor receptor (EGFR) gene are associated with an increased response to gefitinib in patients with non-small cell lung cancer. We have examined the impact of gefitinib on progression-free survival and overall survival in patients with EGFR mutation-positive non-small cell lung cancer. EXPERIMENTAL DESIGN We searched for all clinical trials th...
متن کاملLung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.
PURPOSE Clinical reports about responsiveness to gefitinib treatment in patients of non-small cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor (EGFR) are limited. To increase understanding of the influence of exon 20 mutations on NSCLC treatment with gefitinib, we investigated the clinical features of lung cancer in patients with exon 20 mutations and analy...
متن کاملPremier Lecture Series
Lung cancer is the most common cause of cancer death worldwide, and the majority of cases are associated with cigarette smoking. Non-small cell lung cancer (NSCLC) arising in smokers has a different spectrum of molecular abnormalities than does NSCLC arising in non-smokers, suggesting differences in molecular etiology, pathogene-sis and possibly prognosis. For example, KRAS mutations occur in 2...
متن کاملEGFR mutations and sensitivity to gefitinib.
to the editor: The important study by Dr. Lynch and colleagues (May 20 issue) 1 suggests that specific mutations in the epidermal growth factor receptor (EGFR) characterize a subgroup of non–smallcell lung cancers that may be highly responsive to gefitinib therapy. Do these mutations predict a greater sensitivity to chemotherapy as well? The overall objective response rate to first-line combina...
متن کامل